



ROSALIND DxM (Diagnostic Monitoring System)

INNOVATIVE

With the rapid emergence of SARS-CoV-2 variants, there is rising concern over the detection of new viral strains using the existing diagnostic assays. Diagnostic manufacturers, governments, researchers, and large companies requiring employees to be tested have a vested interest in understanding these variants.


COLLABORATIVE

SCALEABLE

ACTIONABLE

SECURE

In collaboration with the United States National Institutes of Health's (NIH) RADx initiative, ROSALIND launched its web-based platform for monitoring the emergence of SARS-CoV-2 variants as a solution for companies to evaluate the effects on the performance of diagnostic tests. The ROSALIND Diagnostic Monitoring System (ROSALIND DxM) provides the following:




- Secure, scalable web-based system
- Intuitive user interface with protection of proprietary test information
- Advanced Analysis to assess and manage risk
- Reagent coverage and mismatch incident dashboards
- Integrated bioinformatics pipeline (GISAID, GenBank, and FASTA import)

TO LEARN MORE, VISIT WWW.ROSALIND.BIO

ROSALIND truly believes in Research Reimagined! Our goal is to provide you a secure, intuitive, web-based user interface that allows you the ability to quickly get to the relevant, actionable information you need. Here are a few highlights:

Genome Browser Summary




Incident Summary Table

Incident ID	Severity	Age	Count	Category	Product	Manufacturer	Incident Date	Total
ACR0000000001	CRITICAL	10	10	ACR	SARS-CoV-2 Diagnostic PCR Test	ABBOTT	May-28-2021	10
ACR0000000002	CRITICAL	10	10	ACR	SARS-CoV-2 Diagnostic PCR Test	ABBOTT	May-28-2021	10
ACR0000000003	CRITICAL	10	10	ACR	SARS-CoV-2 Diagnostic PCR Test	ABBOTT	May-28-2021	10
ACR0000000004	CRITICAL	10	10	ACR	SARS-CoV-2 Diagnostic PCR Test	ABBOTT	May-28-2021	10
ACR0000000005	CRITICAL	10	10	ACR	SARS-CoV-2 Diagnostic PCR Test	ABBOTT	May-28-2021	10

Detail History Trend



Incident Coverage Map



Whether you are a diagnostic manufacturer, large enterprise, or research scientist, let ROSALIND DxM help you identify, analyze and mitigate potential impacts of SARS-CoV-2 variants.

Standardize Variant Monitoring

Have a consistent, repeatable way to test any variant within diagnostic tests

Accelerate EUA Submission


Easily test and provided required tables for FDA EUA test submission

Post-Market Surveillance

Create and meet key reporting capabilities to ensure test efficacy

Enable Product Refinement

Provide actionable data to refine development of diagnostic tests



TO LEARN MORE, VISIT WWW.ROSALIND.BIO

1 (855) 766-7267

info@rosalind.bio

www.rosalind.bio